Skip to content
naulon

Not checkedNot checked for notices yet.

Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets

Lekha Puri, Collins Oghor, Claudia M Denkinger and 1 more

The Lancet Global Health · 2016

doi:10.1016/s2214-109x(15)00269-7 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is the biggest recent advance in tuberculosis diagnosis, and since 2010 more than 15 million cartridges have been procured through concessional pricing ($9·98 per cartridge in 2015).1 However, even in countries with a high tuberculosis burden, the private sector is not eligible for concessional pricing for Xpert, nor for other WHO-endorsed tests such as line probe assays (LPA) and liquid cultures. Manufacturers set higher prices for reagents and instruments for private laboratories and institutions than for the public sector, and there are additional costs (such as import duties), and margins imposed by distributors, intermediaries, and laboratories.

Abstract licence: CC BY-NC

References5

    5 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.